Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...